According to the research report titled, ‘Global Alpha Emitter Market size study by Type of Radionuclide (Astatine (At-211), Radium (Ra-223), Lead (Pb-212), Bismuth (Bi-212), Actinium (Ac-225), and Other Type of Radionuclides), Medical Application (Prostate Cancer, Bone Metastasis, Ovarian Cancer, Pancreatic Cancer, Endocrine Tumors, and Other Medical Applications), Regional Forecasts 2021-2027’, available with MarketStudyReport, global alpha emitter market is anticipated to register an annual growth rate of 36.7% during 2021-2027.
 

Rising awareness about the benefits of this treatment and increasing prevalence of cancer and cardiac diseases are aiding towards the expansion of global alpha emitter market. As per the data released by American Cancer Society, nearly 22,240 women were speculated to be diagnosed with ovarian cancer in 2018, with around 14,070 women dying from the same.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/4219636/
 

For the unversed, alpha emitters are predominantly used in cancer therapies.  They have the ability to treat ovarian cancer, lymphoma, melanoma, pancreatic cancer among others. The treatment procedure includes different types of radionuclides like bismuth, lead, and radium.
 

On the contrary, rigid regulatory framework and reimbursement issues are likely to hamper global alpha emitter market remuneration scope in the ensuing years.
 

By radionuclide, the marketplace is bifurcated into Astatine (At-211), Radium (Ra-223), Actinium (Ac-225), Lead (Pb-212), Bismuth (Bi-212), and others. In terms of medical application, the industry is split into prostate cancer, bone metastasis, ovarian cancer, ovarian cancer, endocrine tumors, and others.
 

Considering the geographical ambit, regions like North America, Europe, Asia Pacific, and Latin America re considered to understand the dynamics of this industry vertical. The report cites that North America market is projected to amass notable gains during 2021-2027 owing to surging occurrences of cardiac and neurological chronic illnesses across the region.
 

Key players operating in global alpha emitter market are Bayer AG, RadioMedix Inc., Fusion Pharmaceuticals Inc., Telix Pharmaceuticals Inc., IBA RadioPharma Solutions, Actinium Pharmaceutical Inc., and Alpha Tau Medical Ltd.
 

The aforementioned players are undertaking effective strategies like mergers & acquisitions, collaboration, R&D investments, and partnerships to strengthen their presence in the overall market.